Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2014
Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 40 citations in OpenAlex.
- Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.Carcinogenesis · 2016Trial
- Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2015Trial
- Interaction between microRNA and KRAS in Glioblastoma.Current medicinal chemistry · 2026Review
- Nutritional approaches in combating therapeutic resistance and enhancing treatment efficacy in cancer: the impact of ketogenic diets.Nutrition & metabolism · 2025Review
- Review
- The Clinical Significance of MicroRNAs in Colorectal Cancer Signaling Pathways: A Review.Global medical genetics · 2023Review
- Tumor Microenvironment Remodeling in Gastrointestinal Cancer: Role of miRNAs as Biomarkers of Tumor Invasion.Biomedicines · 2023Review
- Regulation of KRAS protein expression by miR-544a and KRAS-LCS6 polymorphism in wild-type KRAS sporadic colon adenocarcinoma.Human cell · 2021Article
- Ketogenic Diet in Cancer Prevention and Therapy: Molecular Targets and Therapeutic Opportunities.Current issues in molecular biology · 2021Review
- Mir-488 alleviates chemoresistance and glycolysis of colorectal cancer by targeting PFKFB3.Journal of clinical laboratory analysis · 2021Article
- Bioinformatic Analysis Identified Potentially Prognostic Long Noncoding RNAs and MicroRNAs for Gastric Cancer.BioMed research international · 2021Article
- New Insights Into Monogenic Causes of Osteoporosis.Frontiers in endocrinology · 2019Review
- (‑)Epigallocatechin‑3‑gallate attenuates anesthesia‑induced memory deficit in young mice via modulation of nitric oxide expression.Molecular medicine reports · 2018Article
- MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside.World journal of gastroenterology · 2018Review
- miR‑3147 serves as an oncomiR in vulvar squamous cell cancer via Smad4 suppression.Molecular medicine reports · 2018Article
- Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors.Frontiers in oncology · 2018Review
- Regulatory miRNAs in Colorectal Carcinogenesis and Metastasis.International journal of molecular sciences · 2017Review
- Deregulation of miR-193b affects the growth of colon cancer cells via transforming growth factor-β and regulation of the SMAD3 pathway.Oncology letters · 2017Article
- MicroRNAs: New Insight in Modulating Follicular Atresia: A Review.International journal of molecular sciences · 2017Review
- MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer.Oncotarget · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeA let-7 microRNA-complementary site (LCS6) polymorphism in the 3' untranslated region of the KRAS gene has been shown to disrupt let-7 binding and upregulate KRAS expression. We evaluated the LCS6 genotype and its association with KRAS mutation status, clinicopathologic features, and disease-free survival (DFS) in patients with stage III colon cancer who enrolled in a phase III clinical trial (NCCTG N0147). EXPERIMENTAL
designThe LCS6 genotype was assayed by real-time PCR in DNA extracted from whole blood (n = 2,834) and compared with paired tumor tissue (n = 977). χ(2) and two-sample t tests were used to compare baseline factors and KRAS mutation status between patients defined by LCS6 variant status. Log-rank tests and multivariate Cox models assessed associations between LCS6 status and DFS, respectively.
resultsWe identified 432 (15.2%) blood samples and 143 (14.6%) tumor samples heterozygous or homozygous for the LCS6 G-allele, and 2,402 of 2,834 (84.8%) blood samples and 834 of 977 (85.4%) tumor samples homozygous for the LCS6 T-allele. Genotype results were highly concordant (99.8%) in cases with paired blood and tumor tissue (n = 977). G-allele carriers were significantly more frequent in Caucasians versus other races (χ(2) test, P < 0.0001). The LCS6 genotype was not associated with KRAS mutation status, clinicopathologic features (all P > 0.2), or DFS (log-rank P = 0.49; HR, 0.929; 95% confidence interval, 0.76-1.14), even after combining LCS6 genotype with KRAS mutation status.
conclusionsIn the largest association study investigating the LCS6 polymorphism in colon cancers, the germline LCS6 genotype was not associated with KRAS mutation status or with clinical outcome in patients with stage III tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.